BiotechTube
DIANA Biotechnologies

DIANA Biotechnologies

Prague, Czech Republic· Est.
dianabiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

DIANA Biotechnologies is a diversified, venture-backed biotech firm leveraging its proprietary DIANA technology platform to serve the diagnostics and life science research markets. Its core business spans four segments: life science reagents (including a high-potency RNase inhibitor and reverse transcriptase), custom oligonucleotide synthesis, monoclonal antibody development, and drug discovery services like kinase inhibitor profiling. Having established itself as a major COVID-19 test producer in Czechia, the company is now targeting global expansion with its portfolio of PCR solutions and high-value research services.

DiagnosticsGenetics & Genomics

Technology Platform

Proprietary DIANA technology platform (exclusive global rights from IOCB Prague) enabling development of high-performance PCR/RT-PCR reagents, ultrasensitive diagnostics, and specialized services like kinase inhibitor profiling.

Funding History

2
Total raised:$2.8M
Seed$2.3M
Grant$500K

Opportunities

The growing global demand for specialized, complex oligonucleotides for advanced diagnostics and research presents a significant opportunity for DIANA's high-margin synthesis service.
Furthermore, the critical unmet need for rapid, sensitive sepsis diagnostics offers a substantial market entry point for their proprietary PCR-based assay.
Expansion into new geographic markets through distributor networks can drive the next phase of growth.

Risk Factors

Intense competition from large, established global players in the PCR reagent and oligo synthesis markets poses a threat to market share and pricing.
The company's historical scale was partially dependent on COVID-19 test production, creating a transition risk to sustainable, non-pandemic revenue streams.
As a relatively small, private company, access to capital for aggressive global expansion and R&D could be a limiting factor.

Competitive Landscape

DIANA competes in fragmented but crowded markets. In life science reagents and oligonucleotides, it faces giants like Thermo Fisher Scientific, Merck (Sigma-Aldrich), and Danaher (IDT, Integrated DNA Technologies). In diagnostics, it competes with major diagnostic firms and specialized sepsis diagnostic companies. Its differentiation lies in its specialized technical expertise in complex oligo modifications, its proprietary enzyme technology, and its agile, service-oriented approach.

More companies in Diagnostics & Precision Medicine →More companies in Czech Republic →